Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Sokhela · SciRah

Researcher profile · Semantic Scholar

S. Sokhela

Share profile

S. Sokhela — researcher profile on SciRah

h-index: 16
Works: 60
Citations: 1,538

Most-cited papers

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
W. D. Venter, Michelle A. Moorhouse, S. Sokhela, L. Fairlie +15 more
2019New England Journal of Medicine614 citations Open access
Semantic Scholar
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
W. D. Venter, S. Sokhela, Bryony Simmons, Michelle A. Moorhouse +17 more
2020The Lancet HIV195 citations
Semantic Scholar
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Cissy M. Kityo, I. Mambule, J. Musaazi, S. Sokhela +16 more
2024Lancet. Infectious Diseases (Print)91 citations Open access
Semantic Scholar
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
Rulan Griesel, G. Maartens, M. Chirehwa, S. Sokhela +4 more
2020Clinical Infectious Diseases81 citations Open access
Semantic Scholar
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes
K. McCann, Shahini Shah, Laura Hindley, A. Hill +5 more
2021AIDS (London)57 citations
Semantic Scholar
Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
Bronwyn Bosch, G. Akpomiemie, N. Chandiwana, S. Sokhela +5 more
2022Clinical Infectious Diseases49 citations Open access
Semantic Scholar
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens
S. Sokhela, W. Venter, Bronwyn Bosch, Joana Woods +22 more
2024Open Forum Infectious Diseases37 citations Open access
Semantic Scholar
Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
T. Pepperrell, A. Hill, Michelle A. Moorhouse, P. Clayden +4 more
2020Journal of virus eradication34 citations Open access
Semantic Scholar
Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors
D. Pepper, Suzaan Marais, R. Wilkinson, F. Bhaijee +8 more
2010BMC Infectious Diseases28 citations Open access
Semantic Scholar
The long wait for long-acting HIV prevention and treatment formulations.
W. D. F. Venter, Monica Gandhi, S. Sokhela, Kenly Sikwese +20 more
2024The Lancet HIV23 citations
Semantic Scholar
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
Tamara Tovar Sanchez, M. Mpoudi-Etame, C. Kouanfack, E. Delaporte +12 more
2023Frontiers in Reproductive Health19 citations Open access
Semantic Scholar
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
J. Rockstroh, R. Paredes, P. Cahn, Jean-Michel Molina +16 more
2025Clinical Infectious Diseases18 citations Open access
Semantic Scholar
Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
Rulan Griesel, A. Kawuma, R. Wasmann, S. Sokhela +6 more
2021British Journal of Clinical Pharmacology18 citations Open access
Semantic Scholar
Weight gain stopping/switch rules for antiretroviral clinical trials
W. D. Francois Venter, S. Sokhela, A. Calmy, Luckyboy Mkhondwane +17 more
2021AIDS (London)18 citations Open access
Semantic Scholar
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
W. D. Venter, Michelle A. Moorhouse, S. Sokhela, Celicia M. Serenata +14 more
2019The Lancet HIV17 citations
Semantic Scholar
Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV
Zinhle Cindi, A. Kawuma, G. Maartens, Y. Bradford +9 more
2022Journal of Infectious Diseases16 citations Open access
Semantic Scholar
Participants on dolutegravir re-suppress HIV RNA after virologic failure: updated data from the ADVANCE trial.
T. Pepperrell, W. D. Venter, K. McCann, Bronwyn Bosch +7 more
2021Clinical Infectious Diseases15 citations Open access
Semantic Scholar
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
S. Asif, Evangelia Baxevanidi, A. Hill, W. D. F. Venter +5 more
2021AIDS (London)14 citations Open access
Semantic Scholar
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial
W. D. Venter, A. Kambugu, M. Chersich, S. Becker +12 more
2018Journal of Acquired Immune Deficiency Syndromes14 citations Open access
Semantic Scholar
Low CD4 counts predict excessive weight gains during first-line treatment for HIV.
Andrew Hill, Tamara Tovar Sanchez, E. Delaporte, S. Sokhela +6 more
2024Journal of Antimicrobial Chemotherapy12 citations Open access
Semantic Scholar
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir- and Tenofovir-containing Regimens
Zinhle Cindi, G. Maartens, Y. Bradford, Francois Venter +4 more
2021Journal of Acquired Immune Deficiency Syndromes12 citations Open access
Semantic Scholar
Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial
Cissy M. Kityo, I. Mambule, J. Musaazi, S. Sokhela +16 more
2025Nature Medicine11 citations Open access
Semantic Scholar
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa
J. Manne-Goehler, June Fabian, S. Sokhela, G. Akpomiemie +6 more
2024Journal of the International AIDS Society11 citations Open access
Semantic Scholar
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
K. Steegen, N. Chandiwana, S. Sokhela, W. D. Venter +1 more
2023AIDS (London)11 citations Open access
Semantic Scholar
Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
Enkosi Mondleki, C. G. Banda, N. Chandiwana, S. Sokhela +4 more
2022Southern African Journal of HIV Medicine11 citations Open access
Semantic Scholar
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial
L. Jamieson, Celicia M. Serenata, Lebogang Makhubele, S. Sokhela +5 more
2021AIDS (London)11 citations Open access
Semantic Scholar
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
A. Kawuma, R. Wasmann, P. Sinxadi, S. Sokhela +5 more
2023CPT: Pharmacometrics & Systems Pharmacology10 citations Open access
Semantic Scholar
Pharmacokinetic and Pharmacogenetic Associations with Dolutegravir Neuropsychiatric Adverse Events in an African Population
Rulan Griesel, P. Sinxadi, A. Kawuma, J. Joska +6 more
2022Journal of Antimicrobial Chemotherapy10 citations Open access
Semantic Scholar
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
C. Orkin, P. Ruane, M. Hedgcock, C. Gaultier +19 more
2026The Lancet9 citations Open access
Semantic Scholar
Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out
Angela Tembo, W. D. F. Venter, S. Sokhela
2024Current Opinion in HIV and AIDS9 citations
Semantic Scholar
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa
Rephaim Mpofu, A. Kawuma, R. Wasmann, G. Akpomiemie +10 more
2024British Journal of Clinical Pharmacology9 citations Open access
Semantic Scholar
Roadmap for Achieving Universal Antiretroviral Treatment
S. Sokhela, S. Lalla-Edward, M. Siedner, M. Majam +1 more
2023Annual Review of Pharmacology and Toxicology8 citations Open access
Semantic Scholar
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
S. Sokhela, Bronwyn Bosch, A. Hill, Bryony Simmons +7 more
2022Journal of Antimicrobial Chemotherapy7 citations Open access
Semantic Scholar
Two-drug regimens for the treatment of HIV in Africa.
I. Mambule, Claire Norcross, Loice Achieng Ombajo, S. Sokhela +5 more
2024The Lancet HIV6 citations
Semantic Scholar
DORA: 48‐week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir‐ or efavirenz‐ to doravirine‐based first‐line antiretroviral therapy
Joana Woods, S. Sokhela, G. Akpomiemie, Bronwyn Bosch +10 more
2024HIV Medicine6 citations Open access
Semantic Scholar
Pharmacogenetics of Tenofovir Renal Toxicity in HIV-positive Southern Africans
Somila Mateza, Y. Bradford, G. Maartens, S. Sokhela +6 more
2023Pharmacogenetics & Genomics5 citations Open access
Semantic Scholar
Integrase inhibitors hand us a new HIV clinical puzzle.
W. D. Francois Venter, S. Sokhela, J. Nel
2022The Lancet HIV4 citations
Semantic Scholar
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid
Jessica Taylor, G. Maartens, S. Sokhela, N. Chandiwana +3 more
2025Southern African Journal of HIV Medicine3 citations Open access
Semantic Scholar
Time to rethink endpoints for new antiretroviral regimen registration? HIV RNA re-suppression in the ADVANCE trial.
T. Pepperrell, W. D. Venter, Michelle A. Moorhouse, K. McCann +6 more
2019AIDS (London)3 citations Open access
Semantic Scholar
Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension
Authors Annie Luetkemeyer, Deborah Donnell, Stephanie E. Cohen, Julia C. Dombrowski +105 more
3 citations
Semantic Scholar
The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis.
Rephaim Mpofu, N. Chandiwana, S. Sokhela, Michelle A. Moorhouse +6 more
2025Journal of Acquired Immune Deficiency Syndromes2 citations
Semantic Scholar
REPRIEVE final results: What does it mean for guidelines in low‐ and middle‐income countries?
S. Sokhela, Jen Manne-Goehler, S. Lalla-Edward, M. Siedner +6 more
2025Journal of the International AIDS Society2 citations Open access
Semantic Scholar
Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV
Zinhle Cindi, A. Kawuma, G. Maartens, Y. Bradford +9 more
2023Pharmacogenetics & Genomics2 citations Open access
Semantic Scholar
Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa
A. Brennan, B. Vetter, S. Masuku, Bukelwa Mtshazo +5 more
2023BMC Public Health2 citations Open access
Semantic Scholar
Overcoming barriers, driving progress: Clinical science at IAS 2025
Ezequiel Cordova, S. Sokhela, J. Alagaratnam, J. Ambrosioni
2026Journal of the International AIDS Society1 citations Open access
Semantic Scholar
Initial HIV Therapy for Adults and Treatment-Associated Weight Gain: The Opti-DOR Randomized Clinical Trial.
Joana Woods, L. Lebina, Karlien Möller, W. D. F. Venter +12 more
2026Journal of the American Medical Association (JAMA)1 citations Open access
Semantic Scholar
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV.
Ana Gabriela Pires Dos Santos, M. Abunimeh, Beatriz Mothe, J. Routy +12 more
2025Contemporary Clinical Trials1 citations Open access
Semantic Scholar
The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa
S. Masuku, A. Brennan, B. Vetter, Francois Venter +5 more
2024BMC Public Health1 citations Open access
Semantic Scholar
High individual pain variability in people living with HIV: A graphical analysis
A. Wadley, Willem D. F. Venter, Michelle A. Moorhouse, G. Akpomiemie +5 more
2020European Journal of Pain1 citations
Semantic Scholar
Weight gain in people with HIV in Africa and Asia: a review of causes, consequences, and management implications.
W. D. F. Venter, S. Sokhela, Jen Manne-Goehler
2026Current Opinion in HIV and AIDS0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Akpomiemie×18
Invite
G. Akpomiemie — researcher profile on SciRah
N. Chandiwana×17
Invite
N. Chandiwana — researcher profile on SciRah
P. Sinxadi×15
Invite
P. Sinxadi — researcher profile on SciRah
Michelle A. Moorhouse×13
Invite
Michelle A. Moorhouse — researcher profile on SciRah

Celicia M. Serenata

×11

Invite

Celicia M. Serenata — researcher profile on SciRah

G. Maartens×11

Invite

G. Maartens — researcher profile on SciRah

Invite

K. McCann — researcher profile on SciRah

Invite

A. Hill — researcher profile on SciRah

Invite

M. Siedner — researcher profile on SciRah

Invite

L. Wiesner — researcher profile on SciRah

W. D. Venter×7

Invite

W. D. Venter — researcher profile on SciRah

Invite

A. Qavi — researcher profile on SciRah